<DOC>
	<DOCNO>NCT02659254</DOCNO>
	<brief_summary>This study small scale pilot trial Sirolimus Target Eluting Bioresorbable Vascular Scaffold ( Firesorb ) Patients Coronary Artery Disease first time . The goal access preliminary safety efficacy Firesorb implantation human body , provide evidence subsequent large-scale , multi-center , randomize control clinical trial . Then provide basis formal application product China .</brief_summary>
	<brief_title>A First-in-Man Study Firesorb BVS ( FUTURE-I )</brief_title>
	<detailed_description>This study prospective , single-center clinical trial . The investigator design recruit 45 subject . After implant Sirolimus Target Eluting Bioresorbable Vascular Scaffold ( Firesorb ) successfully , subject randomly assign queue 1 ( n=30 ) queue 2 ( n=15 ) . The clinical follow-up perform subject 1 month,6 months,1 year,2 years,3 years,4 year 5 year scaffold implantation . Angiographic , IVUS OCT follow-up perform 6 month 2 year scaffold implantation queue 1 ; angiographic , IVUS OCT follow-up perform 1 year 3 year scaffold implantation queue 2 . The primary endpoint study target lesion failure ( TLF ) 30 day scaffold implantation , secondary endpoint series image outcome , evaluation feasibility preliminary safety efficacy product .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . 1875 year age , male nonpregnant female ; 2 . With silent ischemia evidence , patient stable unstable angina , patient old myocardial infarction ; 3 . Total number target lesion 1 ; 4 . Target lesion length ≤ 25mm ( Visual ) ; target lesion diameter 3.0mm 3.75mm ; 5 . Visual assessment target lesion diameter stenosis ≥ 70 % , TIMI blood flow≥1 ; 6 . Each target lesion may cover single stent ; 7 . Patients indication coronary artery bypass graft surgery ; 8 . To understand purpose testing , voluntary inform consent , patient undergo invasive imaging followup . 1 . Within 1 week acute myocardial infarction myocardial enzymes return normal ; 2 . Implantation stent target vessel within 1 year , patient plan intervention within six month ; 3 . Severe congestive heart failure ( NYHA class III ) , leave ventricular ejection fraction &lt; 40 % ( ultrasound leave ventricular angiography ) ; 4 . Preoperative renal function serum creatinine &gt; 2.0mg/DL ; receive hemodialysis ; 5 . Bleeding , active gastrointestinal ulcer , brain hemorrhage subarachnoid hemorrhage half year history ischemic stroke , antiplatelet agent would allow anticoagulant therapy contraindication patient undergo antithrombotic therapy ; 6 . Aspirin , clopidogrel , heparin , contrast agent , poly lactic acid polymer rapamycin allergy ; 7 . The patient 's life expectancy le 12 month ; 8 . Top participate drug medical device meet primary study endpoint clinical trial time frame ; 9 . Researchers determine patient compliance poor , unable complete study accordance requirement ; 10 . Heart transplantation patient ; 11 . The unstable arrhythmia , high risk ventricular extrasystole ventricular tachycardia ; 12 . Cancer need chemotherapy ; 13 . Immunosuppression autoimmune disease , plan undergoing immunosuppressive therapy ; 14 . Planning receive longterm anticoagulant therapy , heparin , warfarin , etc ; 15 . Within six month elective surgery require stop aspirin , Clopidogrel patient ; 16 . Blood test prompt platelet count less 100x10E9/L great 700x10E9/L , white blood cell 3x10E9/L ; know suspect liver disease ( hepatitis ) ; 17 . Peripheral vascular disease , 6F catheter available .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug-Eluting Stents , Absorbable Implants , Stents</keyword>
</DOC>